InMed Completes Key Pharmacokinetic Studies for Alzheimer’s Candidate INM-901

InMed Pharmaceuticals ( (INM) ) has provided an update.

InMed Pharmaceuticals announced the successful completion of pharmacokinetic studies for its Alzheimer’s disease candidate, INM-901, in large animal models. The study demonstrated robust bioavailability and no adverse neural or behavioral effects, supporting the drug’s potential for neurodegenerative disorders. These results will guide the design of human Phase 1 clinical trials and further regulatory interactions, including a pre-IND meeting with the FDA. The company is also advancing its chemistry, manufacturing, and controls development to scale the manufacturing process for INM-901, preparing for further studies and regulatory submissions.

The most recent analyst rating on (INM) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.

Spark’s Take on INM Stock

According to Spark, TipRanks’ AI Analyst, INM is a Underperform.

InMed Pharmaceuticals’ overall stock score is primarily hindered by its financial performance and valuation concerns. The persistent operational losses and negative cash flows are significant risks. Technical analysis indicates a mildly bearish to neutral trend. The recent $5M private placement is a positive development, but it does not outweigh the broader financial challenges.

To see Spark’s full report on INM stock, click here.

More about InMed Pharmaceuticals

InMed Pharmaceuticals is a pharmaceutical drug development company focused on creating a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. Their pipeline includes programs for treating Alzheimer’s, ocular, and dermatological conditions.

Average Trading Volume: 79,534

Technical Sentiment Signal: Sell

Current Market Cap: $4.78M

For an in-depth examination of INM stock, go to TipRanks’ Overview page.